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research project as clinical data, imaging features and 
quality of life evaluation.  
Conclusions: The creation of a formal ontology is the starting 
point to share and collect data from multiple datasets. It 
allows to obtain a clear and a common interpretation of 
concepts, to report information in standardized large 
database. Along these lines the multi-professional team has 
in use a suitable support to implement decision support 
system based on predictive models.  
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Purpose/Objective: To determine patterns of failure (POF) 
and survival outcomes in newly-diagnosed glioblastoma (ND-
GBM) patients treated on prospective phase I and II clinical 
trials using standard chemoradiotherapy in combination with 
novel chemotherapy. 
Materials and Methods: POF of 77 patients with ND-GBM 
enrolled in prospective clinical trials were reviewed. Patients 
received the current standard of care, including surgical 
debulking, conformal radiation therapy (RT), and 
temozolomide, as well as an investigational chemotherapy 
agent (everolimus, erlotinib, or vorinostat). Patients received 
follow-up MR imaging per protocol at 2-month intervals 
following treatment to evaluate response. Contrast 
enhancement (CE) from T1-weighted post-contrast MRI scans 
was used to define each recurrence volume at the time of 
progression (RecVolp). Additionally, the first suspicious scan 
containing new or increased CE was used to define the initial 
recurrence volume (RecVoli). MRI scans were registered to 
the RT planning CT and dose volume histograms were 
calculated for each RecVol. POF at the time of progression 
(POFp) and initial indication (POFi) were characterized by the 
percent volume encompassed within the 95% dose region as 
central (V95% ≥ 95%) or non-central (V95% < 95%). Here, POFp 
and POFi of each patient were categorized as central only, 
non-central only, or both central and non-central. 
Results: Of the collective patient cohort, POF appeared to 
become increasingly non-central and multifocal with time. 
Recurrence with a non-central component increased from 
14% to 27% (p = 0.07) and multifocal recurrence increased 
from 6% to 16% (p = 0.12) from the time of initial indication 
to progression, respectively. POF depended on the novel 
chemotherapy agent given. POFi were (94% central, 6% non-
central, 0% both) for erlotinib, (79%, 0%, 21%) for everolimus, 
and (77%, 18%, 5%) for vorinostat patient cohorts. Patients 
with unmethylated MGMT promoter had a higher percentage 
of multifocal recurrence (40%) compared to those with 
methylated MGMT promoter (0%) at the time of progression 
(p = 0.01). The overall median PFSi, PFSp, and OS were 4.5, 
8.6, and 17.4 months, respectively. Survival outcomes based 
on the novel chemotherapy agent given were not significantly 
different. 
Conclusions: POF for this ND-GBM cohort treated with novel 
chemotherapy agents were predominantly central, but were 
influenced by the time point of analysis. POF of the overall 
cohort were increasingly non-central at progression as 
compared with initial progression, suggesting that recurrence 
originates from the central region. POF differed between 
novel agents despite similar survival outcomes. Robust and 
properly-timed dosimetric POF analysis may be helpful to 
evaluate biologic aspects of novel therapeutic agents.  
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Purpose/Objective: To compare two schedules of 
hypofractionated radiochemotherapy in naive unresectable 
GBM in terms of toxicity, response and survival: the first one 
was followed by low dose radiation therapy (Hypo-RT-
CT+LDRT), in the second schedule no low dose radiation 
therapy was administered (Hypo-RT-CT). 
Materials and Methods: Patients (KPS > 70, age >18 years) 
underwent biopsy or with gross residual tumor after surgery 
were enrolled in these two studies. In the first study (Hypo-
RT-CT), patients received hypofractionated radiotherapy (35 
Gy in ten fractions) combined with Temozolomide (75 mg/mq 
from the start to the end of RT); in the second study (Hypo-
RT-CT+LDRT) patients received hypofractionated 
radiotherapy (30Gy in ten fractions) with concomitant 
Temozolomide. In both studies adjuvant Temozolomide 
(Stupp like) was administered but it was combined with low 
dose radiation therapy (40 cGy twice on day for 5 days) only 
in Hypo-RT-CT+LDRT study. In all cases clinical target volume 
(CTV) was ring enhancement with residual tumor plus 3 cm. 
Acute and late toxicities were evaluated according to 
Common Terminology Criteria for Adverse Events version 4.0. 
MRI was used in order to evaluate the response to the 
treatment, according to RECIST Guidelines. Moreover overall 
survival (OS) and progression-free survival (PFS) were 
calculated by the Kaplan-Mayer method. 
Results: Forty-two patients (M/F: 25/17) were enrolled from 
June 2010 to May 2014. Twenty-two out of 42 patients were 
enrolled in Hypo-RT-CT while 20 pts in Hypo-RT-CT+LDRT 
study. Most of them (57%) was submitted only to a biopsy 
(Table 1). Two out of 22 patients (9%) of Hypo-RT-CT study 
presented acute toxicities G2 (seizure and headache); in 
Hypo-RT-CT+LDRT we recorded G2 acute toxicities in 4 
patients (10%): 2 thrombocytopenia and 2 leucopenia; G3 
acute toxicity was observed only in one patient. After 
hypofractionated radiochemotherapy, partial response (PR) 
and stable disease (SD) were of 22% and 40% respectively in 
Hypo-RT-CT study, 9% and 14% in Hypo-RT-CT+LDRT. Median 
follow-up was of 24 months (range 6 - 53). Median OS and 1-
yrs survival were of 15 months and 75% respectively for Hypo-
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RT-CT and 17 months and 67% for Hypo-RT-CT+LDRT (Fig 1). 
In Hypo-RT-CT and Hypo-RT-CT+LDRT study median PFS were 
of 11 and 10 months respectively. 
 
 
 
Conclusions: LDFRT combined to Temozolomide and 
hypofractionated radiation therapy is a tolerable schedule. It 
seems to improve outcomes when compared to 
hypofractionated schedule with higher dose. We have 
planned a new study in which Hypo-RT-CT is combined with 
LDRT.  
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Purpose/Objective: The feasibility assessment of the in vivo 
multivoxel magnetic resonance spectroscopy (MRS) focused 
on a hippocampal region as the new approach of the study of 
a postradiation cognitive impairment in patients with brain 
metastases (BM) treated by the whole brain radiotherapy 
(WBRT). 
Materials and Methods: 10 patients (6 with lung, 3 with 
breast cancer and 1 with malignant melanoma) with BM 
(median 3 BM, no lesion within 5mm of hippocampus) get 
WBRT (2 laterolateral fields, 3000 cGy in 10 fraction) as part 
of palliative management. Four months after irradiation, 
patients underwent multivoxel MRS (Siemens Symphony, 
1.5T, PRESS-CSI sequence with TE/TR =135 ms/1690 ms, 12 
averages, FOV 120×120 mm). One region of interest was 
placed centrically to cover the whole mesial parts of the both 
temporal lobes with a voxel layer inclined alongside the 
hippocampal long axis in order to examine whole hippocampi 
volume (voxel size set to 10x10x15mm). Postprocessing of 
raw spectroscopic data was performed utilizing LCModel 
(Provencher et al. 2001) for calculation of N-acetylaspartate 
together with N-acetyl aspartylglutamate (tNAA). tNAA are 
ones of commonly detectable brain tissue metabolites that 
are considered as the markers of neuronal density and 
viability. jSIPRO software (Jiru et al., 2013) was utilized for 
final analysis and measurement of tNAA concentration in the 
both hippocampi and separately its anterior and posterior 
portion. 
Results: Using jSIPRO software, it was possible to evaluate 
tNAA concentrations within selected voxels representing the 
hippocampi at overlaid axial T2 image. On average 12 voxels 
were identified within each hippocampus, however, because 
of noise artifacts, 8-11 representative voxels per 
hippocampus were suitable for the concentration analysis. 
Poor-quality spectroscopic data are related especially to the 
anterior parts of the hippocampus because of the diverse 
magnetic susceptibility of surrounding fluid and bony tissues. 
Conclusions: Besides classical singlevoxel MRS, multivoxel 
hippocampal spectroscopic imaging is feasible and well 
tolerated advanced MRI method for the examination of the 
hippocampus in patients after WBRT. For the proper 
calculation of particular metabolites, reading software 
enabling individual voxels selection is necessary since MRS 
from the parts of the anterior hippocampus in the proximity 
of lateral ventricles and bones are biased as proven in our 
study. Care must be taken in selection representative voxels. 
Basic research focusing on metabolite changes within the 
hippocampus after WBRT may bring more light into processes 
responsible for a brain radiation injury. Such results may 
provide more evidence for special approaches leading to a 
brain injury preservation as is currently widely discussed in 
the hippocampal avoidance whole brain radiotherapy or in a 
pharmacotherapy by memantine for example. 
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